Hyperkalaemia
Conditions
Interventions
Treatment includes 3 phases:CP,MP,LTMP.
Eligible participants with hyperkalaemia will enter CP receiving fixed dose of SZC three times daily (TID) for up to 3 days until normokalaemia.Within each coho
Sponsors
Ageishi Yuji
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Provision of written informed consent of the participant or legal representative, and informed assent from the participant (as appropriate) 2. Female or male from birth to 5.0 mmol/L, for participants aged 1 month to 6.0 mmol/L and for participants aged 0 to 6.5 mmol/L at Screening, measured 3 to 14 days prior to first dose of SZC on CP Study Day 1. This should also be confirmed prior to dosing on Day 1. 5. Using digital ECG, QT interval corrected by Bazett's method (QTcB) must meet the age-appropriate parameters at Screening: a. For participants aged 0 to 3 days or less after birth: 3 days to < 12 years: < 440 ms c. For participants aged 12 or more to < 18 years: < 450 ms (male), < 460 ms (female) All QTcB values outside the reference values specified in the protocol should be manually re-measured and re-calculated, and if there is a difference in measurement between the automatic and manual ECG, the manual measurement should always be considered correct. 6. Ability to have repeated blood draws or effective venous catheterisation. 7. Females of childbearing potential must have a negative pregnancy test within one day prior to the first dose of SZC on CP Study Day 1 and sexually active females of childbearing potential must be using 2 forms of medically acceptable contraception with at least one being a barrier method 8. Optional open-label, LTMP only: a. Provision of written informed consent of the participant or legal representative, and informed assent from the participant (as appropriate) to take part in the LTMP. b. Participants who are normokalaemic at the end of MP or hyperkalaemic and not on maximum dose. c. Participants who would benefit from long-term treatment for their hyperkalaemia, as judged by the Investigator.
Exclusion criteria
Exclusion criteria: 1. Neonates with a gestational age < 37 weeks at birth or a birth weight < 2500 g. 2. Term and preterm neonates with suspected conditions predisposing them to intestinal ischaemia (eg, perinatal hypoxia or sepsis). 3. Participants with pseudohyperkalaemia caused by excessive fist clenching to enable venepuncture, by haemolysed blood specimens, or by severe leukocytosis or thrombocytosis. 4. Participants with hyperkalaemia due to soft-tissue damage from crush injury or burns. 5. Participants with hyperkalaemia due to a secondary cause, such as dehydration, excessive use of K+ supplements, or drug use (eg, beta-adrenergic antagonists) and that would be more appropriately treated with other interventions (eg, fluid resuscitation, dose adjustments of medications). 6. Participants with transient iatrogenic hyperkalaemia (eg, due to treatment with tacrolimus). 7. Participants treated with lactulose, rifaximin (XIFAXAN), or other nonabsorbed antibiotics for hyperammonaemia within the last 7 days. 8. Participants treated with CPS, sodium polystyrene sulfonate (eg, KAYEXALATE), or patiromer within the last 4 days prior to first dose of study treatment. 9. Participants with a life expectancy of less than 3 months. 10. Participants who are known to have tested Human Immunodeficiency Virus (HIV) positive. 11. Presence of any condition which, in the opinion of the Investigator, places the participant at undue risk or potentially jeopardises the quality of the data to be generated. 12. Known hypersensitivity or previous anaphylaxis to SZC or to components thereof. 13. Participants with cardiac arrhythmias that require immediate treatment. 14. Participants with a family history of long QT syndrome. 15. Participants on haemodialysis. 16. Participants with a history of bowel obstruction. 17. Participants with severe gastrointestinal disorder or major gastrointestinal surgery (eg, large bowel resection). 18. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site). 19. Previous treatment with SZC. 20. Treatment with a drug or device within the last 30 days prior to first dose of study treatment that has not received regulatory approval at the time of study entry. 21. Previous enrolment in the present study. 22. Females who are pregnant, breastfeeding, or planning to become pregnant. 23. Judgement by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements. 24. If the participant has evidence of Coronavirus disease 2019 (COVID-19) within 2 weeks prior to enrolment (a positive COVID-19 test or suspicion of COVID-19 infection) the participant cannot be enrolled in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correction phase (CP) primary objective: To evaluate the ability to achieve normokalaemia during the CP when initiating treatment with SZC of different dose levels in children with hyperkalaemia 28-day Maintenance Phase (MP) primary objective: To evaluate the ability to maintain normokalaemia during the MP when continuing SZC treatment in children achieving normokalaemia | — |
Countries
Brazil, Canada, China, Gernany, Japan, Poland, Romania, Spain, Ukraine, United Kingdom, United States
Contacts
Public ContactYuji Ageishi
Astrazeneca K.K
Outcome results
None listed